Esquivel VJA, Salinas CMC, Rodríguez AJ, Rendón Pérez AA, Garza EMA

Language: Spanish
References: 20
Page: 58-63
PDF size: 143.38 Kb.

ABSTRACT

Background: reactive protein (CRP), is one of the acute inflammatory markers which are called ‘acute phase reactants’ that are produced in the liver in response to inflammatory or infectious processes. The presence of ANCA formation has been described in patients with tuberculosis (TB).
Objective: Determine the level of CRP, evaluate its behavior as a marker of the inflammatory response and analyze its correlation with ANCAs in patients with TB, before and after initiating treatment for tuberculosis.
Patients: Patients suspected of having TB were selected. Once the diagnosis was confirmed, serum samples were obtained to analyze the clinical and lab data. ANCA determination was done with commercial inmunofluorescence kits and the C-reactive protein with ELISA, before and after the treatment for tuberculosis.
Results: Fifty samples of sera from patients with TB were obtained. In the first (94%) and second (90%) collection of sera the level of Creactive protein registered was less than 5 mg/L. The average level of C-reactive protein was 3.05 ± 8.27 mg/L in the first sample and 4.49 ±11.2 mg/L in the second sample (p = 0.46). ANCA positive patients had higher C-reactive protein levels in their second sample (p = 0.001).
Discusion: There is an association between CRP values and the production of anti-neutrophil cytoplasmic antibodies in a subgroup of patients with TB. Its significance is uncertain, but perhaps they play a role in some pathogenic function in response to pulmonary inflammation.

REFERENCES

1. Unsal E, Aksaray S, Koksal D, Sipit T. Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis. Postgrad Med J 2005;81:604-7.

2. Parikh M, Miller NR, Lee AG, Savino PJ, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006;113:1842-5.

3. Peng Q, Wu Q, Chen CH, Hong H, Zhang LY. Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi 2006;8:208-10.

4. Udvarnoki K, Cervenak L, Uray K, Hudecz F, et al. Antibodies against C-reactive protein cross-react with 60-kilodalton heat shock proteins. Clin Vaccine Immunol 2007;14:335-41.

5. Chierakul N, Kanitsap A, Chaiprasert A, Viriyataveekul R. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion. Respirology 2004;9:66-69.

6. Ito K, Yoshiyama T, Wada M, Ogata H. C-reactive protein in patients with bacteriological positive lung tuberculosis. Kekkaku 2004;79:309-11.

7. Koyanagi A, Kuffo D, Gresely L, Shenkin A, Cuevas LE. Relationships between serum concentrations of C-reactive protein and micronutrients, in patients with tuberculosis. Ann Trop Med Parasitol 2004;98:391-9.

8. Choi CM, Kang CI, Jeung WK, Kim DH, et al. Role of the C-reactive protein for the diagnosis of TB among military personnel in South Korea. Int J Tuberc Lung Dis 2007;11:233-6.

9. Sistema Nacional de Información en Salud (SINAIS). 2005. Dirección URL:

10. Flores-Suarez LF, Cabiedes J, Villa AR, van der Woude FJ, Alcocer-Varela J. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology (Oxford) 2003;42:223-9.

11. Niles JL, McCluskey RT, Ahmad MF, Arnaout MA. Wegener’s granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 1989;1;74:1888-93.

12. Van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985;1:425-9.

13. Gordon C, Luqmani R, Fields P, Howie AJ, Emery P. Two cases of ‘Wegener’s tuberculosis’. Br J Rheumatol 1993;32:143-9.

14. Mahr A, Teixeira L, Jaureguy F, Noeumll L, et al. Low seroprevalence and poor specificity of anti-neutrophil cytoplasm antibodies (ANCA) in tuberculosis [abstract]. Ann Rheu Dis 2004;63:314.

15. Teixeira L, Mahr A, Jaureguy F, Noel LH, et al. Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology (Oxford) 2005;44:247-50.

16. Dannenberg L, Haubitz M, Schaberg T, Hummel S, Globel U. Pulmonary tuberculosis and ANCA [abstract]. Clin Exp Immunol 1998;112:35.

17. Pradhan VD, Badakere SS, Ghosh K, Pawar AR. Spectrum of anti-neutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis overlaps with that of Wegener’s granulomatosis. Indian J Med Sci 2004;58:283-8.

18. Lawn SD, Obeng J, Acheampong JW, Griffin GE. Resolution of the acute-phase response in West African patients receiving treatment for pulmonary tuberculosis. Int J Tuberc Lung Dis 2000;4:340-4.

19. Dorlochter L, Carlsson M, Olafsdottir EJ, Roksund OD, et al. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J Cyst Fibros 2004;3:179-83.

20. Schultz H, Heintz H, van Zandbergen G, Ullrich S, et al. ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener’s granulomatosis patient. Clin Exp Rheumatol 2003;21:763-6.